Boston Scientific buys Israeli medical device co SoniVie

Medical research  credit: Shutterstock
Medical research credit: Shutterstock

The US medical device company will pay up to $540 million for the Rehovot-based intravascular ultrasound device developer for treating high blood pressure.

Medical device giant Boston Scientific has announced that it has signed a definitive agreement to acquire Israeli medical device company SoniVie for an immediate payment of $360 million as well as milestone payments of up to $180 million. Boston Scientific already has a 10% stake in the company.

The biggest winners from the deal are the heirs of the late Shmuel Almagor, Zvika Slovin, formerly of Elron, and European venture capital funds Supernova Invest, Andera Partners, TechWald, and Omega Funds. SoniVie has raised $85 million to date.

SoniVie has developed a tiny intravascular ultrasound device that can selectively denervate nerves around certain blood vessels to treat medical conditions related to high blood pressure. Among other things, the system can treat nerves around the kidney, one of the most effective methods for treating blood pressure. Currently, there are devices on the market that selectively damage nerves around the kidneys, but they use radiofrequency radiation, not ultrasound. Boston Scientific reported that ultrasound energy has the ability to penetrate deep into the tissue, making the treatment more effective and faster.

Last year, SoniVie reported positive results from an initial clinical trial in the US and Israel, and recently began a pivotal trial, which may be sufficient for it to submit the product for FDA approval.

SoniVie was founded in 2014 at the initiative of the Accelmed Fund, led by Uri Geiger, as part of its strategy of building companies after identifying a need from large companies. The technology was initially developed at Cardiosonic, and Accelmed acquired the rights to develop the technology solely for the field of pulmonary hypertension treatment. After Cardiosonic itself went through a crisis, at a time when the market was skeptical about the idea of denerving for the treatment of blood pressure, SoniVie's current investor group led the investment in the company and also acquired Cardiosonic's technology, from which it was spun off, including the technology for the field of denerving in the kidney area, its lead product today.

SoniVie has offices in Rehovot and New Jersey and is currently managed by Tomaso Zambelli, formerly an executive at large medical device companies. The technology was developed by Ariel Sverdlik, who subsequently also invented the medical aesthetics technology of Sofwave Medical (TASE: SOFW), also based on ultrasound.

"I was lucky"

Sverdlik, who developed the technology with SoniVie VP R&D Or Shabtay, recalls how it all began. "I was lucky. I embarked on a doctorate in medical engineering in ultrasound, with the idea of ??using intravascular ultrasound to prevent heart attacks. Tel Aviv University's commercialization company, Ramot, connected me with an investor named Shmuel Almagor. He was a cigarette importer, and perhaps wanted to invest heart disease prevention to deal with feelings of guilt.

"Shmuel asked me - how much money would you need to get FDA approval? I was naive, I said: '$2 million.' After five minutes he calls me, and says 'That's fine'. I asked 'What's fine?' And he said: 'I talked to my wife and she agreed. We will invest in the company.'" Almagor invested over $10 million in the company along the way, but did not live to see the exit.

Initially, the aim of the technology was to prevent the accumulation of calcium deposits in the arteries. "But one day I was at a conference, and I watched a lecture by a new company called Ardian. They talked about a technology for denerving nerves, which they said could capture 5-10% of a $50 billion market. And during the lecture I realized that with ultrasound, I could do it better."

"All the funds decided that this field was nonsense"

Ardian was sold for $800 million to Medtronic, and the market aroused great interest. Sverdlik continues, "Abbott invested $16 million in Cardiosonic in stages." But then, following Medtronic's unsuccessful trial with the technology, the entire field crashed. "Following the failure of the trial, which was not well-planned, all the funds decided that this field was nonsense and that it didn't really work. Abbott stopped injecting the money. When we asked them what to do with their shares, they said - whatever you want."

The entrepreneurs began searching for capital, until they found the AccelMed Fund, which wanted to develop the product for hypertension in health. AccelMed founded SoniVie and acquired the rights to this technology, and subsequently gradually acquired the rest of the technology. This was about the point at which Sverdlik left the company.

"I worked like crazy, and I didn't see any money for five years," he says. "I told them, 'I'm done, I need something new.'" As part of our fund raising efforts, I had met Dr. Shimon Eckhouse, and when I left Cardiosonic, I turned to him and said, 'Let's do something.' He said, 'Your ultrasound, can it denerve the bottom layer of the skin without damaging the top?' I said, 'Absolutely.' And so Sofwave was born," the company now traded on the Tel Aviv Stock Exchange.

Published by Globes, Israel business news - en.globes.co.il - on March 4, 2025.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2025.

Medical research  credit: Shutterstock
Medical research credit: Shutterstock
El Al plane credit: Shutterstock El Al receives state approval to distribute dividend

The Israeli airline has now announced that it will be able to distribute up to 30% of net profit in 2025 and up to 40% in 2026-2028.

Relocation credit: Michal Raz-Haimovitz How to turn the tech relocation tide

With thousands of tech employees leaving Israel, the Innovation Authority proposes measures that could reverse the trend.

groundcover founders credit: Yossi Yarom Israeli observability co groundcover raises $35m

groundcover has developed a “Bring Your Own Cloud” (BYOC) observability solution, redefining the architecture of a modern observability platform.

Tel Aviv Stock Exchange credit: Shutterstock MagioreStock Foreign investment in TASE hits five-year high

Foreign investors have been flocking to the Tel Aviv Stock Exchange in recent weeks, the TASE research department tells "Globes."

Elbit Systems tank turret systems credit: Elbit Systems Elbit Systems wins $100m tank turret systems deal

The Israel defense electronics company will supply its advanced UT30 MK2 unmanned turret systems to General Dynamics European Land Systems (GDELS) to be supplied to a NATO European country.

Tomer Weingarten Photo: PR Trump targets SentinelOne exec in act of revenge

The US administration has suspended the security clearance of the company's chef intelligence and public policy officer Chris Krebs and everyone associated with him.

Tel Aviv Stock Exchange share prices rising credit: Tali Bogdanovsky TASE opens sharply higher after Trump U-turn on tariffs

The pause is being interpreted as a climb down after US President Donald Trump admitted he had made the move to calm the markets.

Ashot Ashkelon credit: Ministry of Defense Up 250%, Ashot Ashkelon wins another Defense Ministry order

The Israeli defense company's share price has risen 250% in the past three years since FIMI Opportunity Funds acquired control.

Liad Agmon credit: Eyal Izhar Insight Partners Liad Agmon steps down as managing partner

Serial entrepreneur Agmon has served as a partner at Insight Partners Israel alongside Daniel Aronovitz who set up the Israel office.

Shekels credit: Shutterstock Vladerina32 Shekel slide resumes amid escalating tariff war

The Bank of Israel is not expected to intervene in the forex market despite the sharp depreciation of the shekel.

Nir Zuk credit: Inbal Marmari Palo Alto Networks mulls buying AI security co for $700m

Sources inform "Globes" that on Palo Alto's radar is Protect AI.

President Donald Trump hosts Prime Minister Benjamin Netanyahu credit: Reuters Kevin Mohatt Israeli officials confident on US tariff concessions

Senior Israeli figures believe that concessions could be tied to progress on strategic regional political issues that are important to President Trump.

Phoenix Investment House CEO Avner Hadad  credit: Tommy Harpaz "The market has priced in all the bad things"

Phoenix Investment House CEO Avner Hadad says US markets could continue to fall, but that we are close to interesting territory for patient investors.

Tel Aviv credit: Shutterstock Tel Aviv slips in World's Wealthiest Cities ranking

Tel Aviv's position as one of the world's wealthiest cities took a big knock over the past year as it slipped from 42nd to 48th in investment advisors Henley & Co.'s "World's Wealthiest Cities" Top 50 ranking.

Leviathan platform  credit: Albatross C'ttee seen recommending no cut in gas exports

The Dayan committee on the future of the gas sector estimates that Israel's natural gas reserves will run out in 2045.

Accountant General Yali Rothenberg credit: Rafi Kutz Israel's fiscal deficit continues to narrow

The deficit narrowed in the twelve months to the end of March 2025, for the sixth consecutive month, Ministry of Finance accountant general Yali Rothenberg reported today.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018